GF
CYT

Gabelli Funds’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Gabelli Funds’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,110,050
Closed -$3.37M – 1141
2023
Q4 		$3.37M Buy
1,110,050
+667,412
+151% +$2.02M 0.03% 540
2023
Q3 		$1.26M Buy
+442,638
New +$1.22M 0.01% 748

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.65B AUM 18.1% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Gabelli Funds's CYT Position: Q1 2024 in Review

Gabelli Funds sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 1,110,050 shares — an estimated $3.37M sold.

Gabelli Funds first reported a position in CYT in Q3 2023 and held it in 2 quarters. The position peaked at $3.37M in Q4 2023. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Gabelli Funds reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Gabelli Funds sold 1,110,050 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.37M.
  • Gabelli Funds first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Gabelli Funds's Cyteir Therapeutics, Inc. Common Stock position peaked at $3.37M in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Gabelli Funds's 13F filing for Q1 2024, filed 14 May 2024.